Episode 56 - Breaking: Four Major Developments Reshaping Ketamine and Psychedelic Therapy
Host Kim Ko covers four major stories from recent months: Matthew Perry case sentencing, France's groundbreaking IV ketamine authorization, Texas regulations update, and Trump's new psychedelic executive order.
In this news roundup episode, we're covering four major developments that have emerged in recent months, all pointing toward increased accountability and oversight in the ketamine and psychedelic therapy space. This isn't our typical interview content - it's breaking news analysis that every provider in this community needs to understand.
We start with the final chapter of the Matthew Perry case, where Jasveen Sangha, known as the "Ketamine Queen," received a 15-year federal prison sentence, while Dr. Salvador Plasencia was sentenced to 30 months for distributing ketamine outside proper medical supervision.
Then we cover France becoming the first country to formally authorize IV racemic ketamine for adults in severe suicidal crisis, with rigorous hospital-based protocols that raise the bar for clinical standards globally.
We continue with updates on Texas Medical Board's proposed ketamine regulations moving toward mandatory clinic registration and stricter oversight, followed by analysis of President Trump's executive order accelerating psychedelic research and creating new federal pathways for investigational compounds.
We wrap up by connecting all four stories to show how legal consequences, international standards, state regulations, and federal policy are collectively signaling that oversight conversations are now happening at the highest levels of government and the field is entering a new era of accountability.
What You'll Learn in This Episode:
Legal accountability implications - How the Matthew Perry case sentencing creates new precedents for physician responsibility when ketamine treatment moves outside supervised clinical settings
International standards development - France's groundbreaking authorization of IV racemic ketamine for suicidal crisis and what their rigorous hospital-based protocols mean for global treatment standards
State regulatory evolution - Current status of Texas Medical Board's proposed ketamine regulations, including mandatory clinic registration and enhanced oversight requirements moving toward a June 2026 vote
Federal policy landscape changes - Analysis of Trump's executive order accelerating psychedelic research access and what new federal pathways mean for the broader psychedelic therapy field
Clinical framework implications - How France's high-surveillance psychiatric intervention model differs from wellness-oriented approaches and why this distinction matters for field credibility
Oversight trends analysis - Why legal consequences, international standards, state regulations, and federal policy are all pointing toward increased accountability requirements for providers
Risk assessment insights - Understanding where legitimate treatment can break down and how unmonitored use creates legal and ethical liability that traces back to prescribing physicians
Future preparation strategies - What these four developments collectively signal about where field standards are heading and how providers can prepare for increased scrutiny
Key Takeaways
Legal consequences are real and precedent-setting - The Matthew Perry case demonstrates that when ketamine moves from supervised clinical settings into unmonitored use, legal accountability doesn't disappear and can result in federal prison sentences for both suppliers and physicians
International validation comes with higher standards - France's authorization of IV racemic ketamine provides meaningful medical credibility but establishes rigorous hospital-based protocols that make it harder to justify programs without equivalent monitoring and outcome evaluation
State regulations are defining minimum operational floors - Texas's proposed rules represent state-level efforts to establish baseline standards below which ketamine therapy shouldn't operate, focusing on clinic registration, physician oversight, and monitoring requirements
Federal policy recognizes psychedelic therapy as legitimate medicine - Trump's executive order signals that psychedelic-assisted therapy is now treated as a serious medical frontier at the federal level, accelerating regulatory and clinical standards conversations
The distinction between medical intervention and wellness service matters - France's framework positions ketamine as a high-surveillance psychiatric intervention rather than a wellness service, a distinction that affects how the field earns lasting credibility
Accountability expectations are escalating at all levels - Legal, state, international, and federal developments collectively indicate that providers who haven't been thinking seriously about documentation, monitoring, and oversight are running out of runway
Unstructured ketamine use is becoming less tolerable - Multiple jurisdictions and authorities are moving simultaneously to restrict unmonitored ketamine administration, requiring providers to meet higher operational standards
Preparation beats reaction in regulatory environments - The providers who will succeed in this evolving landscape are those who proactively adopt rigorous standards rather than waiting to be told what good practice looks like
Listen to the episode on Apple Podcasts, Spotify, Overcast, or on your favorite podcast platform. Watch the discussion on YouTube here.
Episode 56 show notes:
00:06 Episode Introduction
01:28 Matthew Perry Case: The Final Sentence
03:47 France Authorizes IV Ketamine for Suicidal Crisis
07:03 Texas Medical Board Update: PKT Rules Still Pending
08:37 Trump Executive Order: Federal Fast-Track for Psychedelic Therapy
10:43 The REMS Advantage: What Regulatory-Ready Looks Like
12:34 Final Thoughts
Thanks for listening
Prefer to Read?
This episode covers the same content as our comprehensive blog post, Ketamine Therapy Regulations Spring 2026: Perry Sentencing, Texas Rules, France Authorization, and Federal Policy Shifts.
The blog post also includes:
Clickable table of contents for easy navigation
Detailed FAQ section
Links Relevant To The Episode:
Listen to the full story about what’s about to happen in Texas: Episode 049 - Texas Medical Board Proposes Comprehensive Ketamine Therapy Regulations - What It Means for the Industry